NeoGenomics Past Earnings Performance
Past criteria checks 0/6
NeoGenomics's earnings have been declining at an average annual rate of -56.1%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 10.5% per year.
Key information
-56.1%
Earnings growth rate
-55.5%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 10.5% |
| Return on equity | -9.1% |
| Net Margin | -13.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How NeoGenomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 611 | -84 | 321 | 28 |
| 31 Dec 23 | 592 | -88 | 313 | 27 |
| 30 Sep 23 | 575 | -96 | 307 | 27 |
| 30 Jun 23 | 552 | -115 | 309 | 29 |
| 31 Mar 23 | 530 | -126 | 303 | 30 |
| 31 Dec 22 | 510 | -144 | 311 | 30 |
| 30 Sep 22 | 497 | -163 | 293 | 32 |
| 30 Jun 22 | 489 | -147 | 303 | 32 |
| 31 Mar 22 | 486 | -36 | 291 | 27 |
| 31 Dec 21 | 484 | -8 | 284 | 22 |
| 30 Sep 21 | 485 | 49 | 255 | 15 |
| 30 Jun 21 | 489 | 72 | 211 | 10 |
| 31 Mar 21 | 454 | -11 | 196 | 9 |
| 31 Dec 20 | 444 | 4 | 192 | 8 |
| 30 Sep 20 | 425 | -5 | 187 | 8 |
| 30 Jun 20 | 405 | -5 | 184 | 9 |
| 31 Mar 20 | 419 | 3 | 182 | 9 |
| 31 Dec 19 | 409 | 8 | 175 | 8 |
| 30 Sep 19 | 378 | 2 | 164 | 7 |
| 30 Jun 19 | 343 | 2 | 147 | 5 |
| 31 Mar 19 | 309 | 6 | 134 | 3 |
| 31 Dec 18 | 277 | 6 | 114 | 3 |
| 30 Sep 18 | 262 | 8 | 103 | 3 |
| 30 Jun 18 | 252 | -1 | 100 | 4 |
| 31 Mar 18 | 246 | -9 | 96 | 4 |
| 31 Dec 17 | 240 | -11 | 94 | 4 |
| 30 Sep 17 | 239 | -27 | 98 | 4 |
| 30 Jun 17 | 241 | -26 | 98 | 4 |
| 31 Mar 17 | 242 | -29 | 99 | 4 |
| 31 Dec 16 | 232 | -31 | 88 | 5 |
| 30 Sep 16 | 211 | -18 | 85 | 6 |
| 30 Jun 16 | 175 | -12 | 70 | 5 |
| 31 Mar 16 | 136 | -7 | 55 | 5 |
| 31 Dec 15 | 100 | -3 | 41 | 4 |
| 30 Sep 15 | 98 | 0 | 39 | 3 |
| 30 Jun 15 | 96 | 0 | 39 | 3 |
| 31 Mar 15 | 92 | 0 | 38 | 3 |
| 31 Dec 14 | 87 | 1 | 36 | 3 |
| 30 Sep 14 | 80 | 1 | 33 | 3 |
| 30 Jun 14 | 74 | 2 | 31 | 2 |
| 31 Mar 14 | 69 | 2 | 28 | 2 |
| 31 Dec 13 | 66 | 2 | 26 | 2 |
| 30 Sep 13 | 63 | 1 | 25 | 2 |
| 30 Jun 13 | 60 | -1 | 24 | 3 |
Quality Earnings: NG9 is currently unprofitable.
Growing Profit Margin: NG9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NG9 is unprofitable, and losses have increased over the past 5 years at a rate of 56.1% per year.
Accelerating Growth: Unable to compare NG9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NG9 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.5%).
Return on Equity
High ROE: NG9 has a negative Return on Equity (-9.12%), as it is currently unprofitable.